State Board of Administration of Florida Retirement System raised its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 0.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 92,059 shares of the biotechnology company’s stock after purchasing an additional 140 shares during the quarter. State Board of Administration of Florida Retirement System’s holdings in Sarepta Therapeutics were worth $11,159,000 as of its most recent SEC filing.
Other hedge funds also recently modified their holdings of the company. Spire Wealth Management boosted its holdings in shares of Sarepta Therapeutics by 3,666.7% during the 2nd quarter. Spire Wealth Management now owns 226 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 220 shares in the last quarter. First Horizon Advisors Inc. boosted its holdings in shares of Sarepta Therapeutics by 308.3% during the 2nd quarter. First Horizon Advisors Inc. now owns 245 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 185 shares in the last quarter. KB Financial Partners LLC acquired a new stake in shares of Sarepta Therapeutics during the 1st quarter valued at $36,000. AlphaCentric Advisors LLC acquired a new stake in shares of Sarepta Therapeutics during the 2nd quarter valued at $45,000. Finally, Industrial Alliance Investment Management Inc. acquired a new stake in shares of Sarepta Therapeutics during the 2nd quarter valued at $46,000. Institutional investors and hedge funds own 91.82% of the company’s stock.
Sarepta Therapeutics Stock Up 0.4 %
SRPT opened at $127.32 on Tuesday. The stock has a market cap of $11.91 billion, a PE ratio of -16.26 and a beta of 0.93. The company has a quick ratio of 4.90, a current ratio of 5.44 and a debt-to-equity ratio of 1.62. Sarepta Therapeutics, Inc. has a 52 week low of $55.25 and a 52 week high of $159.89. The business’s fifty day simple moving average is $106.99 and its 200 day simple moving average is $106.53.
Wall Street Analysts Forecast Growth
Sarepta Therapeutics Profile
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene.
- Five stocks we like better than Sarepta Therapeutics
- How Investors Can Find the Best Cheap Dividend Stocks
- Udemy stock got boosted by analysts, massive growth at discounts
- With Risk Tolerance, One Size Does Not Fit All
- 3 attractive stocks that insiders are buying
- Insider Buying Explained: What Investors Need to Know
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.